secwatch.observer — SEC 8-K summary
======================================

Issuer:     BullFrog AI Holdings, Inc. (BFRG)
CIK:        0001829247
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001493152-24-052248
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bullfrog AI CEO highlights AI platform advances, LIBD collaboration, BF-114 progress, $8.83M raised in 2024
--------------------------------------------------------------------------------

- bfLEAP platform enhanced with generative and causal AI exclusively licensed from Johns Hopkins APL, enabling explainable AI for target discovery and drug repositioning.
- LIBD collaboration identified novel drug targets for schizophrenia, bipolar disorder, and major depressive disorder; advanced pharma discussions underway.
- BF-114 demonstrated potential in obesity, MASLD, and HCC; published in Cell Reports. Liver disease market projected to exceed $36.5B by 2030.
- Raised $8.83M from two equity offerings in 2024, bolstering cash position for growth initiatives and working capital.
- Strengthened IP with Australian patent for BF-223 (oncology, glioblastoma); added Dr. Chittenden as CSO and Dr. Baldoni to SAB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224052248/0001493152-24-052248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224052248/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-052248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer